• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R.

作者信息

Laorden Daniel, Zamarrón Ester, Romero David, Domínguez-Ortega Javier, Villamañán Elena, Losantos Itsaso, Gayá Francisco, Quirce Santiago, Álvarez-Sala Rodolfo

机构信息

Department of Pneumology, Hospital La Paz, Universidad Autónoma de Madrid, IdiPAZ, and CIBER of Respiratory Diseases, Madrid, Spain.

Department of Pneumology, Hospital La Paz, Universidad Autónoma de Madrid, IdiPAZ, and CIBER of Respiratory Diseases, Madrid, Spain.

出版信息

Respir Med. 2023 May;211:107216. doi: 10.1016/j.rmed.2023.107216. Epub 2023 Mar 21.

DOI:10.1016/j.rmed.2023.107216
PMID:36958514
Abstract
摘要

相似文献

1
Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R.在接受抗IL5/IL5R治疗的真实队列中对FEOS评分和超级应答者标准的评估。
Respir Med. 2023 May;211:107216. doi: 10.1016/j.rmed.2023.107216. Epub 2023 Mar 21.
2
Comparison of Long-term Response and Remission to Omalizumab and Anti-IL-5/IL-5R Using Different Criteria in a Real-life Cohort of Severe Asthma Patients.在重度哮喘患者的真实队列中，使用不同标准比较奥马珠单抗和抗IL-5/IL-5R的长期反应与缓解情况。
Arch Bronconeumol. 2024 Jan;60(1):23-32. doi: 10.1016/j.arbres.2023.11.011. Epub 2023 Nov 22.
3
Severe Asthma Remissions Induced by Biologics Targeting IL5/IL5r: Results from a Multicenter Real-Life Study.靶向白细胞介素 5/白细胞介素 5 受体的生物制剂诱导的重度哮喘缓解：一项多中心真实世界研究的结果。
Int J Mol Sci. 2023 Jan 27;24(3):2455. doi: 10.3390/ijms24032455.
4
Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-analysis.抗 IL-5、抗 IL-5R、抗 IL-13 疗法对哮喘恶化的影响：网络荟萃分析。
Lung. 2020 Feb;198(1):95-103. doi: 10.1007/s00408-019-00310-8. Epub 2020 Jan 1.
5
A comparison of the impact of anti-IL5/5r therapies in allergic versus non-allergic patients with severe eosinophilic asthma in a real-life setting.在现实环境中，抗IL5/5R疗法对重度嗜酸性粒细胞性哮喘的过敏患者与非过敏患者的影响比较。
J Asthma. 2025 Feb;62(2):319-327. doi: 10.1080/02770903.2024.2400607. Epub 2024 Sep 14.
6
Correspondence regarding the paper "Laorden D, Zamarrón E, Romero D, Domínguez-Ortega J, Villamañán E, Losantos I, Gayá F, Quirce S, Álvarez-Sala R. Evaluation of FEOS score and super-responder criteria in a real-life cohort treated with anti-IL5/IL5R. Respir. Med. 2023; 211: 107216".关于论文“Laorden D, Zamarrón E, Romero D, Domínguez-Ortega J, Villamañán E, Losantos I, Gayá F, Quirce S, Álvarez-Sala R. 抗IL5/IL5R治疗的真实队列中FEOS评分和超级应答者标准的评估。《呼吸医学》。2023年；211: 107216”的通信
Respir Med. 2023 Aug;214:107280. doi: 10.1016/j.rmed.2023.107280. Epub 2023 May 10.
7
Increase in FeNO Levels Following IL5/IL5R-Targeting Therapies in Severe Asthma: A Case Series.重度哮喘患者接受IL5/IL5R靶向治疗后呼出气一氧化氮水平升高：病例系列
J Asthma Allergy. 2022 May 19;15:691-701. doi: 10.2147/JAA.S358877. eCollection 2022.
8
Real-world efficacy of treatment with benralizumab, dupilumab, mepolizumab and reslizumab for severe asthma: A systematic review and meta-analysis.真实世界中贝那鲁肽、度普利尤单抗、美泊利单抗和瑞利珠单抗治疗严重哮喘的疗效：系统评价和荟萃分析。
Clin Exp Allergy. 2022 May;52(5):616-627. doi: 10.1111/cea.14112. Epub 2022 Mar 9.
9
Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment.严重哮喘患者的上下气道炎症：精准生物治疗的指导。
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620965151. doi: 10.1177/1753466620965151.
10
Antibodies targeting the interleukin-5 signaling pathway used as add-on therapy for patients with severe eosinophilic asthma: a review of the mechanism of action, efficacy, and safety of the subcutaneously administered agents, mepolizumab and benralizumab.针对白细胞介素-5 信号通路的抗体作为严重嗜酸性粒细胞性哮喘患者的附加治疗药物：皮下给予美泊利珠单抗和贝那利珠单抗的作用机制、疗效和安全性的综述。
Expert Rev Respir Med. 2020 Apr;14(4):353-365. doi: 10.1080/17476348.2020.1718495. Epub 2020 Jan 23.

引用本文的文献

1
Efficacy Assessment of Biological Treatments in Severe Asthma.重症哮喘生物治疗的疗效评估
J Clin Med. 2025 Jan 7;14(2):321. doi: 10.3390/jcm14020321.